AxoGen Q4 Earnings Call Highlights

Hartley said gross profit was negatively impacted by $1.9 million in one-time costs in the fourth quarter associated with the BLA approval, two-thirds of which were non-cash stock-based compensation tied to milestone vesting. Excluding one-time items, she attributed margin pressure mainly to higher product costs related to additional testing steps as Avance transitioned to a biologic, partially offset by fewer inventory write-offs and lower shipping costs following the case stock program’s discontinuation.G ...